Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438262 | 0.84 | RYR2 (0.39) | ALDH1A1MEN1KMT2AHRH3LMNA | |
| SCHEMBL6440113 | 0.75 | ESR1 (0.34) | — | |
| SCHEMBL6436895 | 0.71 | TAAR1 (0.39) | TAAR1SIGMAR1 | |
| SCHEMBL13939397 | 0.71 | HRH3 (0.33) | SMN1; SMN2ALDH1A1MEN1KMT2AHRH3 | |
| SCHEMBL812742 | 0.70 | CA1 (0.58) | ALDH1A1LMNA | |
| SCHEMBL14790755 | 0.69 | IDO1 (0.45) | NPSR1CALM1TAAR1MEN1KMT2A | |
| SCHEMBL29002708 | 0.68 | SMN1; SMN2 (0.48) | SMN1; SMN2NPSR1CALM1TAAR1MEN1 | |
| SCHEMBL6439322 | 0.68 | FFAR1 (0.66) | ALDH1A1F2RL1LMNA | |
| SCHEMBL18027607 | 0.67 | LTA4H (0.50) | SMN1; SMN2KMT2ALMNAHTT | |
| SCHEMBL29205 | 0.67 | CA4 (0.54) | SMN1; SMN2KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-01-22 | — | — | US | disclosed |
| EP-1506959-A2 | Derivatised molecules for mass spectrometry | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023926-A1 | Trityl Derivatives for Enhancing Mass Spectrometry | F3, TBCA, GYPA | SMN1; SMN2 3556/4885NPSR1 3011/4885CALM1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.